TY - JOUR
T1 - Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer
T2 - A Matched Controlled Study
AU - Kronowitz, Steven J.
AU - Mandujano, Cosman Camilo
AU - Liu, Jun
AU - Kuerer, Henry M.
AU - Smith, Benjamin
AU - Garvey, Patrick
AU - Jagsi, Reshma
AU - Hsu, Limin
AU - Hanson, Summer
AU - Valero, Vicente
N1 - Publisher Copyright:
© 2016 by the American Society of Plastic Surgeons.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Background: Although many plastic surgeons perform autologous fat grafting (lipofilling) for breast reconstruction after oncologic surgery, it has not been established whether postoncologic lipofilling increases the risk of breast cancer recurrence. The authors assessed the risk of locoregional and systemic recurrence in patients who underwent lipofilling for breast reconstruction. Methods: The authors identified all patients who underwent segmental or total mastectomy for breast cancer (719 breasts) (i.e., cases) or breast cancer risk reduction or benign disease (305 cancer-free breasts) followed by breast reconstruction with lipofilling as an adjunct or primary procedure between June of 1981 and February of 2014. They also then identified matched patients with breast cancer treated with segmental or total mastectomy followed by reconstruction without lipofilling (670 breasts) (i.e., controls). The probability of locoregional recurrence was estimated by the Kaplan-Meier method. Results: Mean follow-up times after mastectomy were 60 months for cases, 44 months for controls, and 73 months for cancer-free breasts. Locoregional recurrence was observed in 1.3 percent of cases (nine of 719 breasts) and 2.4 percent of controls (16 of 670 breasts). Breast cancer did not develop in any cancer-free breast. The cumulative 5-year locoregional recurrence rates were 1.6 percent and 4.1 percent for cases and controls, respectively. Systemic recurrence occurred in 2.4 percent of cases and 3.6 percent of controls (p = 0.514). There was no primary breast cancer in healthy breasts reconstructed with lipofilling. Conclusions: The study results showed no increase in locoregional recurrence, systemic recurrence, or second breast cancer. These findings support the oncologic safety of lipofilling in breast reconstruction. Clinical Question/Level of Evidence: Risk, II.
AB - Background: Although many plastic surgeons perform autologous fat grafting (lipofilling) for breast reconstruction after oncologic surgery, it has not been established whether postoncologic lipofilling increases the risk of breast cancer recurrence. The authors assessed the risk of locoregional and systemic recurrence in patients who underwent lipofilling for breast reconstruction. Methods: The authors identified all patients who underwent segmental or total mastectomy for breast cancer (719 breasts) (i.e., cases) or breast cancer risk reduction or benign disease (305 cancer-free breasts) followed by breast reconstruction with lipofilling as an adjunct or primary procedure between June of 1981 and February of 2014. They also then identified matched patients with breast cancer treated with segmental or total mastectomy followed by reconstruction without lipofilling (670 breasts) (i.e., controls). The probability of locoregional recurrence was estimated by the Kaplan-Meier method. Results: Mean follow-up times after mastectomy were 60 months for cases, 44 months for controls, and 73 months for cancer-free breasts. Locoregional recurrence was observed in 1.3 percent of cases (nine of 719 breasts) and 2.4 percent of controls (16 of 670 breasts). Breast cancer did not develop in any cancer-free breast. The cumulative 5-year locoregional recurrence rates were 1.6 percent and 4.1 percent for cases and controls, respectively. Systemic recurrence occurred in 2.4 percent of cases and 3.6 percent of controls (p = 0.514). There was no primary breast cancer in healthy breasts reconstructed with lipofilling. Conclusions: The study results showed no increase in locoregional recurrence, systemic recurrence, or second breast cancer. These findings support the oncologic safety of lipofilling in breast reconstruction. Clinical Question/Level of Evidence: Risk, II.
UR - http://www.scopus.com/inward/record.url?scp=84955584393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955584393&partnerID=8YFLogxK
U2 - 10.1097/01.prs.0000475741.32563.50
DO - 10.1097/01.prs.0000475741.32563.50
M3 - Article
C2 - 26818270
AN - SCOPUS:84955584393
SN - 0032-1052
VL - 137
SP - 385
EP - 393
JO - Plastic and reconstructive surgery
JF - Plastic and reconstructive surgery
IS - 2
ER -